R/R CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors | VuMedi

Find latest CLL videos · 100+ videos

Cleveland Clinic Taussig Cancer Institute

R/R CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors

By Cleveland Clinic Taussig Cancer Institute FEATURING Brian Hill

By Cleveland Clinic Taussig Cancer Institute FEATURING Brian Hill

53 views

June 25, 2024

Frontline Therapy & Early Treatment Results

00:00

Sequencing After Frontline Therapy & Double Refractory Challenges

02:47

Real-World Outcomes for Double Refractory CLL/SLL

05:45

Overcoming Resistance: Combination Therapy & CAR-T Options

06:35

Evaluating PI3 Kinase Inhibitors & Alternative Treatments

08:59

Introducing Pirtobrutinib: An FDA-Approved Therapy

11:02

Pirtobrutinib Efficacy & Subgroup Response Analysis

16:16

Comments 0

Login to view comments. Click here to Login